Clinical Trial

A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

Study acronym: LUMIRAY
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This global, open-label, single arm, phase 1b study aims to learn more about whether a treatment called JNJ-90301900 is safe and effective when injected directly into tumors, along with standard chemotherapy and radiation therapy, for participants with head and neck squamous cell cancer (HNSCC; a type of solid tumor that begins in outer tissue layer of the mouth \& throat).
Protocol Amendment History 2 changes
notable Enrollment increased: 30 -> 45 participants 2026-07-03
notable Trial sites expanded: 12 -> 16 locations 2026-05-09
Trial Details
NCT Number NCT07219212
Lead Sponsor Johnson & Johnson Enterprise Innovation Inc.
Conditions Squamous Cell Carcinoma of Head and Neck
Enrollment 45 participants
Start Date 2026-01-26
Primary Completion 2028-07-14 (estimated)
Study Completion 2028-07-14 (estimated)
Updated on ClinicalTrials.gov 2026-07-31